ES2965017T3 - Micropartículas que comprenden un compuesto que contiene azufre - Google Patents
Micropartículas que comprenden un compuesto que contiene azufre Download PDFInfo
- Publication number
- ES2965017T3 ES2965017T3 ES17735616T ES17735616T ES2965017T3 ES 2965017 T3 ES2965017 T3 ES 2965017T3 ES 17735616 T ES17735616 T ES 17735616T ES 17735616 T ES17735616 T ES 17735616T ES 2965017 T3 ES2965017 T3 ES 2965017T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- microparticles
- cysteamine
- stabilizing agent
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Accessories For Mixers (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346969P | 2016-06-07 | 2016-06-07 | |
| GBGB1609940.0A GB201609940D0 (en) | 2016-06-07 | 2016-06-07 | Microparticles |
| PCT/GB2017/051637 WO2017212249A1 (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2965017T3 true ES2965017T3 (es) | 2024-04-10 |
Family
ID=56508202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17735616T Active ES2965017T3 (es) | 2016-06-07 | 2017-06-06 | Micropartículas que comprenden un compuesto que contiene azufre |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11369568B2 (enExample) |
| EP (1) | EP3463325B1 (enExample) |
| JP (1) | JP7195934B2 (enExample) |
| KR (1) | KR102412212B1 (enExample) |
| CN (1) | CN109310654A (enExample) |
| AU (1) | AU2017277897B2 (enExample) |
| BR (1) | BR112018075221B1 (enExample) |
| CA (2) | CA3026743C (enExample) |
| DK (1) | DK3463325T3 (enExample) |
| ES (1) | ES2965017T3 (enExample) |
| FI (1) | FI3463325T3 (enExample) |
| GB (1) | GB201609940D0 (enExample) |
| MX (1) | MX2018014278A (enExample) |
| SG (1) | SG11201810934TA (enExample) |
| WO (1) | WO2017212249A1 (enExample) |
| ZA (1) | ZA201807852B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
| ES3024695T3 (en) * | 2018-10-17 | 2025-06-05 | Novabiotics Ltd | Cysteamine for use in the treatment of lung diseases |
| JP2023540985A (ja) * | 2020-09-03 | 2023-09-27 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 噴霧乾燥低吸湿性活性粉末組成物 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CN118871100A (zh) * | 2021-12-07 | 2024-10-29 | 西拉治疗公司 | 抗病毒治疗剂及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8901570D0 (sv) | 1989-05-02 | 1989-05-02 | Draco Ab | Organic salts of cysteine derivatives |
| CN101094651B (zh) * | 2004-12-30 | 2011-03-09 | 多贝尔有限公司 | 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法 |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| AU2007338210B2 (en) | 2006-12-22 | 2013-01-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| WO2010060875A1 (de) | 2008-11-27 | 2010-06-03 | Boehringer Ingelheim International Gmbh | Neue pulverförmige kristalline arzneimittel zur inhalation |
| AU2010210620B2 (en) * | 2009-02-03 | 2016-02-25 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| WO2010138419A2 (en) | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| JP6012716B2 (ja) | 2011-05-19 | 2016-10-25 | サヴァラ，インク． | 乾燥粉末バンコマイシン組成物および関連する方法 |
| JP5981123B2 (ja) * | 2011-10-11 | 2016-08-31 | サンサ コーポレーション （バルバドス） インク | ニコチン薬の製造法およびその方法により製造される医薬 |
| BR112014009789A2 (pt) * | 2011-10-26 | 2017-04-25 | Seattle Children's Res Inst | cisteamina no tratamento da doença fibrótica |
| US9493775B2 (en) * | 2012-02-10 | 2016-11-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
| ITMI20130572A1 (it) | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| CA2926793C (en) * | 2013-10-11 | 2022-11-22 | Lawrence S. ZISMAN | Spray-dry formulations for treating pulmonary arterial hypertension |
| GB201416716D0 (en) | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| US10905660B2 (en) * | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
-
2016
- 2016-06-07 GB GBGB1609940.0A patent/GB201609940D0/en not_active Ceased
-
2017
- 2017-06-06 AU AU2017277897A patent/AU2017277897B2/en active Active
- 2017-06-06 KR KR1020187035476A patent/KR102412212B1/ko active Active
- 2017-06-06 US US16/307,990 patent/US11369568B2/en active Active
- 2017-06-06 MX MX2018014278A patent/MX2018014278A/es unknown
- 2017-06-06 FI FIEP17735616.9T patent/FI3463325T3/fi active
- 2017-06-06 WO PCT/GB2017/051637 patent/WO2017212249A1/en not_active Ceased
- 2017-06-06 CN CN201780035360.7A patent/CN109310654A/zh active Pending
- 2017-06-06 SG SG11201810934TA patent/SG11201810934TA/en unknown
- 2017-06-06 BR BR112018075221-5A patent/BR112018075221B1/pt active IP Right Grant
- 2017-06-06 EP EP17735616.9A patent/EP3463325B1/en active Active
- 2017-06-06 ES ES17735616T patent/ES2965017T3/es active Active
- 2017-06-06 JP JP2018563831A patent/JP7195934B2/ja active Active
- 2017-06-06 CA CA3026743A patent/CA3026743C/en active Active
- 2017-06-06 CA CA3096121A patent/CA3096121C/en active Active
- 2017-06-06 DK DK17735616.9T patent/DK3463325T3/da active
-
2018
- 2018-11-21 ZA ZA2018/07852A patent/ZA201807852B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014278A (es) | 2019-03-14 |
| KR102412212B1 (ko) | 2022-06-23 |
| US11369568B2 (en) | 2022-06-28 |
| CA3026743C (en) | 2024-05-28 |
| RU2018142841A (ru) | 2020-06-04 |
| BR112018075221A2 (pt) | 2019-03-19 |
| AU2017277897B2 (en) | 2022-09-08 |
| CA3026743A1 (en) | 2017-12-14 |
| ZA201807852B (en) | 2023-05-31 |
| KR20190016957A (ko) | 2019-02-19 |
| EP3463325B1 (en) | 2023-11-08 |
| JP2019517541A (ja) | 2019-06-24 |
| EP3463325A1 (en) | 2019-04-10 |
| SG11201810934TA (en) | 2019-01-30 |
| AU2017277897A1 (en) | 2018-12-20 |
| US20190175501A1 (en) | 2019-06-13 |
| GB201609940D0 (en) | 2016-07-20 |
| BR112018075221B1 (pt) | 2024-02-06 |
| DK3463325T3 (da) | 2024-01-02 |
| FI3463325T3 (fi) | 2023-12-19 |
| NZ748596A (en) | 2025-06-27 |
| CA3096121C (en) | 2022-11-15 |
| WO2017212249A1 (en) | 2017-12-14 |
| CA3096121A1 (en) | 2017-12-14 |
| CN109310654A (zh) | 2019-02-05 |
| JP7195934B2 (ja) | 2022-12-26 |
| RU2018142841A3 (enExample) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2965017T3 (es) | Micropartículas que comprenden un compuesto que contiene azufre | |
| US10905660B2 (en) | Microparticles | |
| KR100958235B1 (ko) | 아미노글리코시드의 폐 전달 | |
| CA2981038C (en) | Dry powder vancomycin compositions and associated methods | |
| ES2406405T3 (es) | Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares | |
| US9539233B2 (en) | Gallium formulation for the treatment and prevention of infectious diseases | |
| US20210154137A1 (en) | Dry powder vancomycin compositions and associated methods | |
| CA2515262C (en) | Treatment of bacterial diseases of the respiratory organs | |
| WO2004052333A1 (en) | Pharmaceutical compositions for the pulmonary delivery of aztreonam | |
| RU2780397C2 (ru) | Микрочастицы, содержащие серосодержащие соединения | |
| ES2918193T3 (es) | Polvo medicamentoso para administración por inhalación y un proceso del mismo | |
| EP4433029A2 (en) | Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders | |
| Auriemma et al. | Gentamicin and particle engineering: from an old molecule to innovative drug delivery systems | |
| IL263540B2 (en) | Microparticles that include a sulfur-containing compound | |
| Manniello et al. | PhD Thesis in Drug delivery to the lung in Cystic Fibrosis: deposition, dissolution, mucus interaction and microbiological evaluation of dry powder inhalers. | |
| NZ618002B2 (en) | Dry powder vancomycin compositions and associated methods |